Validation of an AI-based Histologic Prognostic Biomarker in Patients with Non–muscle-invasive Bladder Cancer Using the Prospective Swedish National Register of Urinary Bladder Cancer

European Urology Oncology · Published 2026-08-01 · DOI 10.1016/j.euo.2026.07.002

Authors (3)

Per-Uno Malmström, Anca Dragomir, Truls Gårdmark

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Malmström, P., Dragomir, A., Gårdmark, T. (2026). Validation of an AI-based Histologic Prognostic Biomarker in Patients with Non–muscle-invasive Bladder Cancer Using the Prospective Swedish National Register of Urinary Bladder Cancer. European Urology Oncology. https://doi.org/10.1016/j.euo.2026.07.002

Related articles

• Oncological Outcomes of Different Managements of the Distal Ureter in Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma · European Urology Oncology · 2026 · Same journal
• Prognostic Factors for Recurrence and Survival After Radical Cystectomy for Non–muscle-invasive Bladder Cancer: A Multicenter Analysis of 1032 Patients · European Urology Oncology · 2026 · Same journal
• When Patients Refuse Radical Cystectomy: Integrating Trimodality Therapy in the Perioperative ICI/ADC Era · European Urology Oncology · 2026 · Same journal
• Doublet Versus Triplet Therapy in High-volume Metastatic Hormone-sensitive Prostate Cancer Patients with Bone Metastases: Results from the ARON-3 Study · European Urology Oncology · 2026 · Same journal
• Individual Patient Data Validation of the EAU Definitions of BCG Failure in Patients with Non–muscle-invasive Urothelial Carcinoma of the Bladder: An International Multicenter Retrospective Study · European Urology Oncology · 2026 · Same journal
• Salvage High-intensity Focused Ultrasound for Prostate Cancer Recurrence after Radiotherapy (HIFI-2 Study) · European Urology Oncology · 2026 · Same journal
• PI-RADS v2 and Adverse Prostate Cancer Outcomes: A Cross-cohort Replication Study Across Three Centers · European Urology Oncology · 2026 · Same journal
• Study Protocol of OLIGOPELVIS 2–GETUG P12: A Randomized Phase 3 Study Comparing Intermittent Androgen-deprivation Therapy with or Without Salvage High-dose Intensity-modulated Radiotherapy to Oligorecurrent Pelvic and Para-aortic Lymph Nodes in Patients with Biochemically Relapsing Prostate Cancer · European Urology Oncology · 2026 · Same journal
• Outcomes of Intermediate Risk Non–muscle-invasive Bladder Cancer Receiving Adjuvant Treatment: A Pooled Analysis of Four Randomized Controlled Trials · European Urology Oncology · 2026 · Same journal
• Adjusted Comparison of First-line Enfortumab Vedotin Plus Pembrolizumab Versus Platinum-based Chemotherapy ± Avelumab Maintenance for the Treatment of Locally Advanced/Metastatic Urothelial Carcinoma · European Urology Oncology · 2026 · Same journal